2021
Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients.
Sharpe J, Schnell P, Knopp M, Binzel K, Magyer M, Cherian M, Gatti-Mays M, Pariser A, Wesolowski R, Sardesai S, VanDeusen J, Stover D, Ramaswamy B, Williams N, DeVries A, Shinde N, Orchard T, Lustberg M. Phase II double blinded randomized placebo-controlled trial of minocycline to ameliorate chemotherapy-induced cognitive changes in breast cancer (BC) patients. Journal Of Clinical Oncology 2021, 39: e12528-e12528. DOI: 10.1200/jco.2021.39.15_suppl.e12528.Peer-Reviewed Original ResearchPET/CT imagingPET/CTCytokine levelsMicroglial activationCT imagingF-fluorodeoxyglucoseDouble-blinded randomized placebo-controlled trialBlinded randomized placebo-controlled trialChemotherapy-induced cognitive changesRandomized placebo-controlled trialCognitive functionPlacebo-controlled trialInflammatory cytokine levelsBreast cancer patientsCognitive changesCT brain imagingAC therapyDaily minocyclinePotent mitigatorNeoadjuvant chemotherapyPlacebo groupInflammatory markersInflammatory changesMedian ageMinocycline group
2015
Impact of breast cancer treatment on body mass index (BMI) over time.
Reinbolt R, Pan X, Wandell K, Pilarski R, Layman R, Mrozek E, Ramaswamy B, Wesolowski R, Lustberg M. Impact of breast cancer treatment on body mass index (BMI) over time. Journal Of Clinical Oncology 2015, 33: 94-94. DOI: 10.1200/jco.2015.33.28_suppl.94.Peer-Reviewed Original ResearchBody mass indexBreast cancer patientsEndocrine therapyAromatase inhibitorsWeight gainBMI changeCancer patientsEarly placebo-controlled trialsInitial body mass indexEarly-stage breast cancerHigher body mass indexBody mass index (BMI) changeBreast cancer patient cohortsPlacebo-controlled trialRetrospective chart reviewStage breast cancerBreast cancer treatmentCancer patient cohortsBreast cancer therapyQuality of lifeDifferent treatment groupsAI therapyChart reviewTreatment initiationMass index